Finance

Human Papillomavirus (HPV)-induced Cancers: First Patient Enrolled in Phase I/IIa Clinical Trial for Lenti-HPV-07, the TheraVectys’ Therapeutic Vaccine Candidate Against Oropharyngeal and Cervical Cancers

October 4, 2024

[#item_full_content]PARIS–(BUSINESS WIRE)– #LentiHPV07–First patient enrolled in Phase I/IIa clinical trial for Lenti-HPV-07, the TheraVectys vaccine candidate against oropharyngeal and cervical cancers.